로그인시 본인확인과정이 필요할 수 있습니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기
| 국가/구분 | United States(US) Patent 등록 |
|---|---|
| 국제특허분류(IPC7판) |
|
| 출원번호 | US-0099612 (2013-12-06) |
| 등록번호 | US-8933059 (2015-01-13) |
| 발명자 / 주소 |
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 | 피인용 횟수 : 10 인용 특허 : 521 |
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estra
Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
1. A pharmaceutical composition comprising: a solubilizing agent, the solubilizing agent comprising an effective amount of a C6-C12 oil;0.5 mg estradiol or 0.52 mg estradiol hemihydrate, the estradiol or estradiol hemihydrate being at least about 90% solubilized in the solubilizing agent; and100 mg
1. A pharmaceutical composition comprising: a solubilizing agent, the solubilizing agent comprising an effective amount of a C6-C12 oil;0.5 mg estradiol or 0.52 mg estradiol hemihydrate, the estradiol or estradiol hemihydrate being at least about 90% solubilized in the solubilizing agent; and100 mg progesterone;wherein a portion of the progesterone is suspended; andwherein the estradiol or the estradiol hemihydrate and the suspended progesterone are uniformly dispersed. 2. The pharmaceutical composition of claim 1, wherein the solubilizing agent is selected from at least one of monoglycerides, diglycerides, triglycerides, and combinations thereof, wherein the monoglycerides, diglycerides, and triglycerides are predominantly of C6-C12 fatty acid chain lengths. 3. The pharmaceutical composition of claim 2, wherein the monoglycerides, diglycerides, and triglycerides are >50% C6-C12 fatty acid chain lengths. 4. A pharmaceutical composition comprising: about 100 mg progesterone;about 0.5 mg estradiol or about 0.52 mg estradiol hemihydrate, the estradiol or estradiol hemihydrate being at least about 90% solubilized;about 196.48 mg of monoglycerides and diglycerides of caprylic acid and capric acid (CAPMUL MCM); andabout 3.0 mg of at least one of lauroyl macrogol-32 glycerides EP, lauroyl polyoxyl-32 glycerides NF, or lauroyl polyoxylglycerides (GELUCIRE 44/14);wherein a portion of the progesterone is suspended; andwherein the estradiol or the estradiol hemihydrate and the suspended progesterone are uniformly dispersed. 5. A method comprising administering an effective amount of pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising: about 100 mg progesterone;about 0.5 mg estradiol, the estradiol being at least about 90% solubilized in the solubilizing agent;about 196.48 mg of monoglycerides and diglycerides of caprylic acid and capric acid (CAPMUL MCM); andabout 3.0 mg of at least one of lauroyl macrogol-32 glycerides EP, lauroyl polyoxyl-32 glycerides NF, or lauroyl polyoxylglycerides (GELUCIRE 44/14);wherein a portion of the progesterone is suspended; andwherein the estradiol and the suspended progesterone are uniformly dispersed. 6. The method of claim 5, wherein the pharmaceutical composition is administered as a continuous-combined therapy regimen. 7. The method of claim 5, wherein the pharmaceutical composition is administered a sequentially-combined therapy regimen. 8. A method comprising administering an effective amount of a pharmaceutical composition comprising: 0.5 mg estradiol or about 0.52 mg estradiol hemihydrate, the estradiol or estradiol hemihydrate being about 90% solubilized, the estradiol being at least about 90% solubilized in the solubilizing agent;100 mg progesterone; and 7 a solubilizing agent, the solubilizing agent comprising an effective amount of a C6-C12 oil;wherein a portion of the progesterone is suspended;wherein the estradiol and the suspended progesterone are uniformly dispersed; andwherein the pharmaceutical composition is administered once daily for the treatment of symptoms associated with menopause. 9. The method of claim 8, wherein the pharmaceutical composition is administered as a continuous-combined therapy regimen. 10. The method of claim 8, wherein the pharmaceutical composition is administered as a sequentially-combined therapy regimen. 11. The method of claim 8, wherein the solubilizing agent is selected from at least one of monoglycerides, diglycerides, triglycerides, and combinations thereof, wherein the monoglycerides, diglycerides, and triglycerides are predominantly of C6-C12 fatty acid chain lengths. 12. The method of claim 11, wherein the monoglycerides, diglycerides, and triglycerides are >50% C6-C12 fatty acid chain lengths.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.